LIST OF TABLES
UU
TABLE 1 SKIN DISEASES IN THE U.S. 46
TABLE 2 HEALTH CARE SPENDING IN THE U.S. IN 2017 IN USD MILLION 48
TABLE 3 DRUG APPROVAL PROCESS 52
TABLE 4 PRICES OF SURVEYED PRESCRIPTION DRUGS 56
TABLE 5 PRICES OF DRUGS DERMATOLOGY DRUGS IN USD 57
TABLE 6 BIOLOGICS COMPLETED STUDIES FOR PSORIASIS TREATMENT IN THE U.S. 60
TABLE 7 DERMATOLOGY DRUGS SIDE EFFECTS 66
TABLE 8 U.S. DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 70
TABLE 9 U.S. CORTICOSTEROIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 71
TABLE 10 U.S. ANTIFUNGAL DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 73
TABLE 11 U.S. SYNTHETIC IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 73
TABLE 12 U.S. IMIDAZOLES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 74
TABLE 13 U.S. IMMUNOSUPPRESSIVE DRUGS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 75
TABLE 14 U.S. MONOCLONAL ANTIBODIES IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 76
TABLE 15 U.S. RETINOIDS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 77
TABLE 16 U.S. ANTIBIOTICS AGENT IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 78
TABLE 17 U.S. ANTIVIRAL AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 79
TABLE 18 U.S. ANTIHISTAMINES AGENTS IN DERMATOLOGY DRUGS MARKET, BY DRUG CLASS, 2018-2027 (USD MILLION) 80
TABLE 19 U.S DERMATOLOGY DRUGS MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION) 82
TABLE 20 U.S DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, 2018-2027 (USD MILLION) 85
TABLE 21 U.S. DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 88
TABLE 22 U.S INFECTIOUS SKIN DISEASE IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 89
TABLE 23 U.S BACTERIAL IN INFECTIOUS SKIN DISEASE IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 89
TABLE 24 U.S VIRAL IN INFECTIOUS SKIN DISEASE IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 90
TABLE 25 U.S FUNGAL IN INFECTIOUS SKIN DISEASE IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 91
TABLE 26 U.S INFLAMMATORY/AUTOIMMUNE DISORDERS IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 92
TABLE 27 U.S PIGMENTATION DISORDERS IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 92
TABLE 28 U.S HYPERPIGMENTATION IN PIGMENTATION DISORDERS IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 93
TABLE 29 U.S HYPOPIGMENTATION IN PIGMENTATION DISORDERS IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 93
TABLE 30 U.S SKIN CANCER IN DERMATALOGY DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION) 94
TABLE 31 U.S DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 96
TABLE 32 U.S TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 97
TABLE 33 U.S SEMI-SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 97
TABLE 34 U.S LIQUID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 98
TABLE 35 U.S SOLID TOPICAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 98
TABLE 36 U.S ORAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 99
TABLE 37 U.S PARENTAL IN DERMATOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 100
TABLE 38 U.S. DERMATOLOGY DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION) 102
TABLE 39 U.S. DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 105
LIST OF FIGURE
LIST OF FIGURES
FIGURE 1 U.S. DERMATOLOGY DRUGS MARKET: SEGMENTATION 21
FIGURE 2 U.S. DERMATOLOGY DRUGS MARKET: DATA TRIANGULATION 23
FIGURE 3 U.S. DERMATOLOGY DRUGS MARKET: DROC ANALYSIS 24
FIGURE 4 U.S. DERMATOLOGY DRUGS MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 U.S. DERMATOLOGY DRUGS MARKET : COMPANY RESEARCH ANALYSIS 25
FIGURE 6 U.S. DERMATOLOGY DRUGS MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 U.S. DERMATOLOGY DRUGS MARKET: VENDOR SHARE ANALYSIS 28
FIGURE 8 U.S. DERMATOLOGY DRUGS MARKET: SEGMENTATION 31
FIGURE 9 INCREASING PREVALENCE OF SKIN DISEASES AND RISE IN SPENDING ON HEALTH CARE ARE DRIVING THE U.S. DERMATOLOGY DRUGS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 32
FIGURE 10 CORTICOSTEROIDS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. DERMATOLOGY DRUGS MARKET IN 2020 & 2027 32
FIGURE 11 FIG 1.: LIST OF MARKETED DERMATOLOGY DRUGS 33
FIGURE 12 FIG 2.: PRODUCT PIPELINE 42
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF U.S. DERMATOLOGY DRUGS MARKET 45
FIGURE 14 NUMBER OF CARED-FOR INDIVIDUALS IN U.S. 47
FIGURE 15 HEALTH CARE SPENDING IN THE U.S. IN 2017 48
FIGURE 16 PRESCRIPTION DRUGS SPENDING IN THE U.S. IN 2010-2020 49
FIGURE 17 PRESCRIPTION DRUGS SPENDING, RETAIL AND NONRETAIL SETTINGS, IN THE U.S. IN 2013-2020 49
FIGURE 18 TOTAL R&D PIPELINE SIZE, BY YEAR, 2001-19 58
FIGURE 19 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018 59
FIGURE 20 THE R&D PIPELINE BY THERAPY GROUP, 2018 AND 2019 59
FIGURE 21 U.S. DERMATOLOGY DRUGS MARKET: BY DRUG CLASS, 2019 70
FIGURE 22 U.S DERMATOLOGY DRUGS MARKET: BY DRUG TYPE, 2019 82
FIGURE 23 U.S DERMATOLOGY DRUGS MARKET: BY PRESCRIPTION MODE, 2019 85
FIGURE 24 U.S. DERMATALOGY DRUGS MARKET: BY INDICATION, 2019 88
FIGURE 25 U.S DERMATOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2019 96
FIGURE 26 U.S. DERMATOLOGY DRUGS MARKET: BY END USER, 2019 102
FIGURE 27 U.S. DERMATOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2019 105
FIGURE 28 U.S DERMATOLOGY DRUGS MARKET: COMPANY SHARE 2019 (%) 107
